Alibaba Unveils NextGeneration Zhenwu AI Chip and Large Language Model to Bolster Cloud and AI Ambitions Eli Lilly Commits 4 Billion to Vaccine Development in Trio of Deals Assurant AIZ Stock Outlook Wall Street Sentiment Remains Cautiously Optimistic Huawei to Introduce Enhanced Smartphone Chips This Fall Intensifying Competition with Nvidia and Apple Perpetua Resources Secures 29 Billion US Loan for Idaho GoldAntimony Project Apples WWDC in Focus as AI Strategy Faces Key Test ROIV Q1 2026 Earnings Missed Estimates as Pipeline Progress Takes Center Stage Viavi Solutions VIAV Q1 2026 Earnings EPS Surges Past Estimates as Shares Rise HOVNP Q1 2026 Earnings Preferred Stock Reports NarrowerthanExpected Loss on Strong Operating Trends BAH Q1 2026 Earnings Strong EPS Surprise Drives Positive Stock Reaction Indaptus Therapeutics Inc INDP Q4 2025 Earnings Deeper Loss Yet Shares Surge on Pipeline Progress Shinhan Financial Group Q4 2025 Earnings EPS Falls Short as Net Income Pressures Mount ABVC BioPharma Consolidates at 139 as Support and Resistance Levels Narrow Revelation Biosciences Inc REVB Edges Lower Maintains Support Near 101 Middlesex Water MSEX Holds Steady Near Key Support as Trading Range Persists Japan Smaller Capitalization Fund JOF Edges Higher Amid Modest Gains Radiopharm Theranostics RADX Holds Steady at 449 Consolidation Phase for Radiopharma Play Prediction Markets Signal Growing Odds of Fed Rate Hike by Mid2027 Limoneira LMNR Q1 2026 Earnings EPS Misses Estimates Amid Operational Pressures Stock Eases PLDT Inc PHI Holds Steady Near Support as Telecom Sector Faces Headwinds ZBIO Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Phase ROP Q1 2026 Earnings EPS Surpasses Estimates Amid Operational Discipline ATEC Earnings Overview 20260527 TTWO Q1 2026 Earnings EPS Surges 393 Above Estimates ONCY Q3 2025 Earnings Clinical Progress Overshadows WiderThanExpected Loss DSGR Q1 2026 Earnings EPS Exceeds Estimates Despite Stock Decline Alaunos Therapeutics TCRT Q4 2023 Earnings WiderthanExpected Loss as PreRevenue Biotech Advances Pipeline